Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Common link between Type 2 diabetes and autism

A review of the genetic and biochemical abnormalities associated with autism reveals a possible link between the widely diagnosed neurological disorder and Type 2 diabetes, another medical disorder on the rise in recent decades.

20 Oct 2011

Medication therapy management in interprofessional heath care

Akinyele and other University of Maryland School of Pharmacy students at the Mercy Health Clinic in Gaithersburg, Md. are learning firsthand about the remarkable effectiveness of medication therapy management (MTM), a hot new pharmacy trend in interprofessional heath care.

19 Oct 2011

Accera identifies genetic profile of AD patients with heightened response to Axona

Accera, Inc., a biotech company specializing in cognitive health, announced today that it has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona (AC-1202), a prescription medical food product available at pharmacies nationwide.

18 Oct 2011

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc., and Takeda Global Research & Development Centre (Europe), Ltd., announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes.

18 Oct 2011

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin (trastuzumab), experienced comparable results to Herceptin given as an intravenous infusion.

18 Oct 2011

Scientists identify genes that act in muscles to modulate aging and resistance to stress

Researchers at Emory University School of Medicine have identified a set of genes that act in muscles to modulate aging and resistance to stress in fruit flies.

18 Oct 2011

National award encourages bio-science student researchers

A key challenge for the bio-sciences sector is to keep its best research graduates in science and in Australia. The national student awards recognise and encourage promising research students and raise awareness of biosciences research translation and applications.

17 Oct 2011

Myths and misconceptions about diabetes

November is designated American Diabetes Month and while raising awareness this month about preventing diabetes is important, focusing on proper treatment is just as important for those living with the disease.

15 Oct 2011

Emory researcher provides overview on 'CVD and PCOS' in APS conference

Sarah Berga, MD, former Chair of the Department of Gynecology and Obstetrics at the Emory University School of Medicine, is a researcher whose work focuses on understanding the impact of metabolic and psychological stresses on the reproductive system and as a cause of infertility, as well as on PCOS. She will provide an overview of her team's work in a presentation entitled, "CVD and PCOS." Her remarks are part of the Physiology of Cardiovascular Disease: Gender Disparities conference, October 12 at the University of Mississippi in Jackson.

15 Oct 2011

NIH awards Scripps Research scientist for research into Type I diabetes

A scientist at The Scripps Research Institute has been awarded $4.2 million from the National Institutes of Health in a program to advance what the agency calls "bold and creative research" into Type I diabetes.

14 Oct 2011

Echo Therapeutics to begin Symphony tCGM System clinical study in Type 1 and Type 2 diabetes

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced that it is initiating a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 diabetes.

13 Oct 2011

Researchers identify age-dependent beta cell proliferation pathway

As a person ages, the ability of their beta cells to divide and make new beta cells declines. By the time children reach the age of 10 to 12 years, the ability of their insulin-producing cells to replicate greatly diminishes. If these cells, called beta cells, are destroyed-as they are in type 1 diabetes-treatment with the hormone insulin becomes essential to regulate blood glucose levels and get energy from food.

13 Oct 2011

Halloween health tips for parents of children with diabetes

Ghosts, ghouls and goblins are suiting up for the yearly pilgrimage through neighborhoods shouting "Trick or Treat!" and begging for sweet treats that are synonymous with Halloween.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

World class scientist presents fourth Environmental Microbiology Lecture

World class scientist Professor Willem M. de Vos will explain next Monday how the microbes that are closest to our hearts - gut microbes - could underpin a new way of thinking about human biology. As well as looking at our own genes, we can now include those of our microbes in studies of human health and disease. This is a significant shift in the way we approach human biology.

11 Oct 2011

Sirt1 protein enhances skeletal muscle insulin sensitivity in calorie-restricted mice

The number of individuals with type 2 diabetes is reaching epidemic proportions. One of the main risk factors for developing type 2 diabetes is resistance of cells in the body (particularly liver, fat, and skeletal muscle cells) to the effects of the hormone insulin.

11 Oct 2011

Case Western Reserve wins NCI grant to study genetic determinants of esophageal cancer

Case Western Reserve University School of Medicine and the Case Comprehensive Cancer Center are proud to announce the receipt of a highly competitive $5.4 million grant to study genetic determinants of Barrett's esophagus and esophageal adenocarcinoma.

11 Oct 2011

Rare and severe hypoglycemia could be genetic

The life-threatening condition depicts the fact that the body does not have enough energy to function. Scientists at the University of Cambridge say mutations in the AKT2 gene are to blame. Writing in the journal Science, they say there are already cancer drugs which target a similar process.

10 Oct 2011